ArticleBMC medical imaging2026
CT-based hepatic and splenic extracellular volume fraction and iodine washout rate for noninvasive assessment of portal hypertension: a preliminary study.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CT-derived hepatic extracellular volume fraction for the assessment of graft rejection after liver transplantation: a retrospective observational study.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn cirrhotic patients, the severity of portal hypertension (PH) directly correlates with the risk of decompensation. The hepatic venous pressure gradient (HVPG) is critical for staging and prognostic prediction of PH, but it is invasive. Non-invasive assessment of PH remains an unmet clinical need. Therefore, this study aimed to evaluate whether multiphasic computed tomography (CT)-derived extracellular volume fraction (ECV) of the liver and spleen, and the liver iodine washout rate (IWR), could serve as noninvasive biomarkers for clinically significant PH (CSPH, defined as HVPG ≥ 10 mmHg) and severe PH (defined as HVPG ≥ 16 mmHg).
methodsThis retrospective study included 127 participants: 76 cirrhotic patients with CSPH and 51 control individuals with normal liver (as determined by clinical data, laboratory tests and imaging). All participants underwent contrast-enhanced CT. Pearson correlations between CT parameters and HVPG were analyzed. The diagnostic performance of these parameters in differentiating patients with CSPH from control individuals, and non-severe PH (HVPG < 16 mmHg) from severe PH was assessed using the areas under the receiver operating characteristic curve (AUC).
resultsThe CT parameters significantly differed between CSPH patients and control individuals (P < 0.05). ECVliver, ECVspleen, and IWRliver were correlated with HVPG (r = 0.29, 0.41, and − 0.45, respectively; all P < 0.05). Both ECVspleen and IWRliver independently predicted PH severity (P < 0.05), and showed excellent diagnostic accuracy for CSPH (AUC = 0.981 and 0.953, respectively), outperforming ECVliver (AUC = 0.706, P < 0.001). For distinguishing non-severe PH from severe PH, ECVspleen and IWRliver achieved AUC values of 0.718 and 0.722, respectively, with their combination improving diagnostic accuracy (AUC = 0.832, sensitivity = 90.00%, and specificity = 69.44%).
conclusionThe CT parameters ECVspleen and IWRliver can serve as promising noninvasive tools for assessing PH severity. Further validation in broader PH cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.